- Home
- HKIT vs BLRX Comparison
HKIT vs BLRX Comparison
Compare HKIT & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKIT
- BLRX
- Stock Information
- Founded
- HKIT 1996
- BLRX 2003
- Country
- HKIT China
- BLRX Israel
- Employees
- HKIT N/A
- BLRX N/A
- Industry
- HKIT Computer Software: Prepackaged Software
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- HKIT Technology
- BLRX Health Care
- Exchange
- HKIT Nasdaq
- BLRX Nasdaq
- Market Cap
- HKIT 39.8M
- BLRX 15.3M
- IPO Year
- HKIT 2023
- BLRX 2011
- Fundamental
- Price
- HKIT $1.43
- BLRX $4.70
- Analyst Decision
- HKIT
- BLRX Strong Buy
- Analyst Count
- HKIT 0
- BLRX 2
- Target Price
- HKIT N/A
- BLRX $19.00
- AVG Volume (30 Days)
- HKIT 8.2K
- BLRX 77.4K
- Earning Date
- HKIT 04-29-2025
- BLRX 08-14-2025
- Dividend Yield
- HKIT N/A
- BLRX N/A
- EPS Growth
- HKIT N/A
- BLRX N/A
- EPS
- HKIT N/A
- BLRX N/A
- Revenue
- HKIT $2,904,950.00
- BLRX $22,340,000.00
- Revenue This Year
- HKIT N/A
- BLRX N/A
- Revenue Next Year
- HKIT N/A
- BLRX N/A
- P/E Ratio
- HKIT N/A
- BLRX N/A
- Revenue Growth
- HKIT N/A
- BLRX 91.68
- 52 Week Low
- HKIT $1.15
- BLRX $2.30
- 52 Week High
- HKIT $1.86
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- HKIT 60.28
- BLRX 57.56
- Support Level
- HKIT $1.33
- BLRX $4.05
- Resistance Level
- HKIT $1.45
- BLRX $4.64
- Average True Range (ATR)
- HKIT 0.05
- BLRX 0.38
- MACD
- HKIT 0.01
- BLRX -0.01
- Stochastic Oscillator
- HKIT 100.00
- BLRX 86.17
About HKIT Hitek Global Inc.
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.